Strata Critical Medical, Inc.(SRTA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,616 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
SRTA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Strata Critical Medical, Inc. (SRTA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SRTA at 47.0/100 on a 32-signal composite quality model, placing it at rank #1,616 of 2,879 stocks — the bottom half of the AI-ranked universe. SRTA scores in the top quartile across balance sheet strength (94.1), profitability (90.7), institutional flow (75.6). Areas of concern include free cash flow (11.9) and revenue growth (15.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Strata Critical Medical, Inc. reports quarterly revenue of $67.4M, net income of $2.2M, free cash flow of $-1.3M. Top institutional holders of SRTA by reported 13-F value include ARK Investment Management, Third Point, BlackRock,, based on the most recent SEC filings. SRTA trades on the Nasdaq exchange and files with the SEC under CIK 1779128. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SRTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Strata Critical Medical, Inc. directly from SEC EDGAR. Strata Critical Medical, Inc.'s 13F Pro composite quality score has ranged between 31 and 47 since 2024, currently 47.0 — an improving long-term trajectory across 15 quarterly and live scoring snapshots.
Revenue
Q1 2026
$67.4M
Net Income
Q1 2026
$2.2M
Free Cash Flow
Q1 2026
$-1.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+34.3% YoYNet Income
+251.4% YoYOperating Income
+0.8% YoYEPS (Diluted)
+242.9% YoYTotal Assets
+26.8% YoYTotal Debt
Op. Cash Flow
-1841.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $197.1M +34.3% | $146.8M -34.8% | $225.2M +54.1% | $146.1M | — |
| Net Income | $41.3M +251.4% | $-27.3M +51.3% | $-56.1M -105.7% | $-27.3M -21443.9% | $127.7K |
| Operating Income | $-22.4M +0.8% | $-22.5M +66.9% | $-68.1M -27.3% | $-53.5M -7789.5% | $-678.5K |
| EPS (Diluted) | $0.50 +242.9% | $-0.35 +53.9% | $-0.76 -100.0% | $-0.38 | — |
| Total Assets | $325.5M +26.8% | $256.7M -13.0% | $294.9M -9.3% | $325.0M +17.0% | $277.8M |
| Total Debt | — | — | — | $0.00 | — |
| Operating Cash Flow | $-48.9M -1841.8% | $-2.5M +92.2% | $-32.3M +12.9% | $-37.1M -4573.6% | $-794.5K |
AI Insight: SRTA Financial Trends
SRTA posts its first net profit in eight quarters in Q1 2026 ($2M), but operating losses persist and cash flow remains erratic.
• Net income turned positive to $2M in Q1 2026, the first profitable quarter since at least Q2 2024.
• Operating cash flow recovered to $4M in Q1 2026 after four consecutive quarters of negative or near-zero OCF.
• Operating income has remained negative in six of eight quarters, ranging from -$3M to -$17M, signaling persistent core operating losses.
• Equity grew from $229M in Q2 2024 to $286M in Q1 2026, a modest strengthening of the balance sheet over the period.
⚠ Q3 2025 showed anomalous $57M net income on only $5M revenue and -$37M OCF — likely a one-time item requiring clarification.
⚠ Revenue remains volatile, swinging from $5M in Q3 2025 to $67M–$71M in adjacent quarters, raising top-line visibility concerns.
⚠ Debt data is entirely absent across all periods — leverage position is unassessable, a meaningful information gap.
AI Insight: SRTA Ratio Trends
SRTA's operating losses are narrowing sharply — Q1 2026 operating margin of -4.4% is the least negative in the dataset — but ROIC remains negative across nearly every quarter.
• Operating margin improved from -47.6% in Q4 2024 to -4.4% in Q1 2026, the least negative reading in the dataset.
• Q1 2026 net profit margin turned positive at 3.2% and ROE reached 3.0%, the first positive readings in any reported quarter.
• ROIC has remained negative in every quarter except Q3 2024 (9.2%), including -4.2% in Q1 2026, signaling persistent capital inefficiency.
• Q3 2025 shows extreme anomalies: -65.0% operating margin alongside 81.2% ROE and 68.5% ROA, suggesting a large non-operating one-off item.
⚠ ROIC has never sustainably turned positive; whether the Q1 2026 improvement in profitability translates to positive ROIC is the key inflection to monitor.
⚠ The Q3 2025 ROE/ROA spike (81.2% / 68.5%) versus negative operating margin warrants scrutiny — the nature of the one-off gain could mask underlying weakness.
⚠ TTM net profit margin of 22.4% far exceeds any single quarter's NPM, implying the Q3 2025 non-operating gain heavily distorts the trailing-twelve-month picture.
Get alerted when SRTA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Strata Critical Medical, Inc. including:
Top Institutional Holders of SRTA
ARK Investment Management LLC
$31.2M7,455,284 shThird Point LLC
$20.9M5,000,000 shBlackRock, Inc.
$19.1M4,568,268 shNorthern Right Capital Management, L.P.
$17.1M4,090,169 shVANGUARD CAPITAL MANAGEMENT LLC
$12.0M2,872,446 shAWM Investment Company, Inc.
$11.8M2,821,468 shROYCE & ASSOCIATES LP
$11.8M2,816,372 shPillsbury Lake Capital LLC
$10.9M2,603,796 shFirst Eagle Investment Management, LLC
$9.5M2,266,243 shGEODE CAPITAL MANAGEMENT, LLC
$7.1M1,699,710 sh
| Fund | Value | Shares |
|---|---|---|
| ARK Investment Management LLC | $31.2M | 7,455,284 |
| Third Point LLC | $20.9M | 5,000,000 |
| BlackRock, Inc. | $19.1M | 4,568,268 |
| Northern Right Capital Management, L.P. | $17.1M | 4,090,169 |
| VANGUARD CAPITAL MANAGEMENT LLC | $12.0M | 2,872,446 |
| AWM Investment Company, Inc. | $11.8M | 2,821,468 |
| ROYCE & ASSOCIATES LP | $11.8M | 2,816,372 |
| Pillsbury Lake Capital LLC | $10.9M | 2,603,796 |
| First Eagle Investment Management, LLC | $9.5M | 2,266,243 |
| GEODE CAPITAL MANAGEMENT, LLC | $7.1M | 1,699,710 |
More Healthcare Companies
View all Healthcare →Put SRTA on your watchlist
Track score changes the day Strata Critical Medical, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SRTA a good stock to buy?
13F Pro's AI-powered analysis of Strata Critical Medical, Inc. (SRTA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SRTA are available on the SRTA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own SRTA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SRTA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Strata Critical Medical, Inc.'s investment landscape.